These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Characterization of [(3)H]idazoxan binding sites on human platelets.
    Author: Ruiz J, Barinagarrementeria G, Martín-Gómez JI, Callado LF, Meana JJ.
    Journal: Platelets; 2002 Jun; 13(4):241-6. PubMed ID: 12189026.
    Abstract:
    Human platelets possess at least two non-adrenoceptor binding sites pharmacologically distinct from the alpha(2)-adrenoceptors. The effects of various imidazol(in)es on platelet aggregation have suggested that these compounds may interact with these non-adrenoceptor binding sites on platelets. [(3)H]Idazoxan is an antagonist of the alpha(2)-adrenoceptors frequently used to characterize imidazoline I(2) receptors. We evaluated the binding of [(3)H]idazoxan to human platelet membranes. In saturation experiments [(3)H]idazoxan (1.25-32 nM) recognized a single, saturable binding site with high affinity. However, competition assays revealed the presence of alpha(2A)-adrenoceptors and a non-adrenoceptor minor population (25-39%) recognized with high affinity by the imidazoline drug with low affinity for alpha(2)-adrenoceptors 2-BFI. After the addition of (-)adrenaline (5 microM) to mask alpha(2)-adrenoceptors, competition curves against [(3)H]idazoxan binding were biphasic. The imidazoline I(1) receptor-selective drugs, efaroxan and rilmenidine, recognized the minor component with high affinity, whereas the imidazoline I(2) receptor-selective drugs, guanabenz and 2-BFI, bound with high affinity to the major component. Further masking experiments in the presence of efaroxan (2 microM) or guanabenz (1 microM) confirmed that [(3)H]idazoxan labels two non-adrenoceptor binding sites pharmacologically compatible with imidazoline I(1) and I(2) receptors as well as alpha(2A)-adrenoceptors in human platelets.
    [Abstract] [Full Text] [Related] [New Search]